# CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.

> **NCT07742839** · — · NOT_YET_RECRUITING · sponsor: **Edwards Lifesciences** · enrollment: 168 (estimated)

## Conditions studied

- Atrial Appendage

## Interventions

- **DEVICE:** Edwards ECLIPTIS Left Atrial Appendage Exclusion System

## Key facts

- **NCT ID:** NCT07742839
- **Lead sponsor:** Edwards Lifesciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2027-07-10
- **Final completion:** 2030-08-29
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742839, "CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07742839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*